Biocept, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Darrell Taylor
- Full Time Employees
- 50
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 9955 Mesa Rim Road San Diego CA United States of America 92121
- IPO Date
- Feb 5, 2014
- CIK
- 0001044378
- Website
- biocept.com
- Similar Companies
- Business
- Biocept, Inc. is a molecular diagnostics company specializing in developing and performing clinical laboratory tests to aid patients with metastatic cancers, particularly those with central nervous system (CNS) involvement. The company offers proprietary diagnostic assays including its CNSide™ platform, which isolates and analyzes cerebrospinal fluid tumor cells (CSF-TCs) and cell-free DNA (cfDNA) to provide actionable molecular information for personalized cancer treatment planning. Biocept's product portfolio includes liquid biopsy assays for various carcinomas and melanomas, and it provides services to medical oncologists, neuro-oncologists, biopharmaceutical companies conducting clinical trials, and cancer researchers. The company operates its CLIA-licensed, CAP-accredited laboratory primarily in the United States, with a focus on biomarkers and rare event detection for oncology patients. Founded in 1997 and headquartered in San Diego, California, Biocept has expanded its commercial offerings to cater to multiple cancer types that metastasize to the CNS, including lung, breast, and melanoma cancers. The company also provides assay development services tailored to pharmaceutical and biotechnology clients for clinical study applications such as patient population profiling and treatment efficacy measurement. Recent significant developments include the commercial launch of its CNSide cerebrospinal fluid assay to improve metastatic cancer diagnostics, a relocation and expansion of its laboratory facilities in San Diego to increase testing capacity, and a successful ramp-up in processing volumes reaching over 60,000 samples per month. Biocept has also pursued key collaborations to enhance its diagnostic capabilities and extend its market reach. In the last 1-2 years, Biocept undertook a strategic expansion of its test offerings with a focus on the CNSide platform, incorporating new assays optimized for melanoma metastases detection. The company has also been active in operational growth, increasing its workforce and upgrading its infrastructure for higher throughput and cost efficiency. Despite these advancements, Biocept filed for voluntary liquidation under Chapter 7 bankruptcy in October 2023 in the U.S. Bankruptcy Court for the District of Delaware, indicating restructuring or cessation of operations. Nevertheless, Biocept continues to support clinical and biopharmaceutical partnerships, delivering advanced molecular diagnostics to improve outcomes for metastatic cancer patients within North America. In summary, Biocept, Inc. remains a specialized diagnostics firm focused on molecular testing products and services for metastatic cancer management, leveraging proprietary liquid biopsy technologies to deliver precise clinical insights through its CNSide assay platform, while undergoing recent operational expansions and facing significant financial restructuring.
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
Biocept to Participate in the H.C. Wainwright Global Investment Conference
Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)
Biocept to Hold Business Update Conference Call on August 30, 2023
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Biocept Reports Second Quarter 2023 Financial Results
Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference
Biocept's CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference
Biocept Announces the Passing of Board Chair M. Faye Wilson
Biocept appoints Antonino Morales as president and chief executive officer
Biocept Names Antonino Morales as President and Chief Executive Officer
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023
Biocept says poster presentation at ASCO highlights impressive performance of CNSide assay in detecting leptomeningeal metastases
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept's CNSide™ Versus Cytology
Why Is Biocept (BIOC) Stock Down 42% Today?
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
Biocept shares to commence trading on split-adjusted basis
Biocept Announces One-for-Thirty Reverse Stock Split
Biocept Announces One-for-Thirty Reverse Stock Split